-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Functional indigestion (FD) is one of the most common functional gastrointestinal diseases (FGIDs), and researchers found a 21 percent prevalence of FD in a random survey of 321,000 people worldwide.
increased risk of FD among smokers, people infected with Helicobacterrobacteria, and people taking nonsteroidal anti-inflammatory drugs.
FD is still a general term, referring to patients with upper abdominal pain syndrome (EPS) and after-dinner distress syndrome (PDS).
main symptoms of EPS are upper abdominal pain and burning sensations, one or both of which occur at least once a week.
more and more clinicians recognize the value and importance of antidepressants in treating FD patients.
study was conducted to observe the therapeutic effect of small doses of amitrin (AMT) on upper abdominal pain syndrome (EPS) in patients with functional indigestion.
in this study, 60 EPS patients were randomly divided into two groups for a four-week clinical trial: the general treatment of pythonazole (RT group) and the AMT treatment group.
RT group was treated with 40mg torazole daily.
amT group received 25mg AMT treatment daily before going to bed.
the Nepean Indigestion Index (NDI) checklist, the Hamilton Anxiety/Depression Scale (HAMA/HAMD) and the Pittsburgh Sleep Quality Index (PSQI) assessed indigestion symptoms, psychological distress, and sleep, respectively.
results showed that all variables in both groups were similar before treatment (0 weeks).
4 weeks of treatment, the AMT group's NDI-symptom checklist score and EPS severity and annoyance were significantly reduced compared to the RT group.
, there was no difference between the two groups in terms of post-treatment EPS mental state (HAMD/HAMA score) or sleep quality (PSQI score).
, after 4 weeks of treatment, the AMT group had a shorter sleep time than the RT group.
amT was effective in improving indigestion symptoms and sleep time in EPS patients compared to pythonazole, although it did not improve mental state, the study authors concluded.
, AMT can be considered the ideal drug for clinical EPS therapy.
